Immune/EpiCept Merge To Form Multi-Project Antibody Drug Company
This article was originally published in The Pink Sheet Daily
Executive Summary
Israeli antibody drug developer Immune Pharmaceuticals will have several projects in the pipeline, including some potential out-licensing candidates, after it makes the leap to a U.S. public company through a reverse-merger with troubled EpiCept, CEO Daniel Teper said during an interview at BIO CEO.